Albireo Sets Sights On Rare Disease Model

First Indication Under Review, With Plans For Two More

19 Feb 2021

Anticipating approval this summer of the first drug for PFIC, Albireo hopes to add Alagille syndrome and biliary atresia to odevixibat labeling. Firm has modeled its commercial plans on the success of other rare disease firms.

Brainstorming Group of people Working Concept. Business team brainstorming. Marketing plan researching. Paperwork on the table, laptop and mobile phone. — Albireo looked at the successes of other rare disease firms as it moves toward its first approval

By modeling its commercial plans on other companies’ successes with rare disease drugs, Albireo Pharma Inc. thinks it can eventually derive blockbuster annual sales from lead candidate odevixibat, which is under US Food and Drug Administration review for approval to treat progressive familial intrahepatic cholestasis (PFIC) but is also in late-stage development for other cholestatic liver diseases.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Novartis Gains Further Renal Territory With Regulus Acquisition

30 Apr 2025

• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.